Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of -14.91% and Operating profit at 7.05% over the last 5 years
3
The company has declared Negative results for the last 6 consecutive quarters
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,280 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
-0.30
-7.25%
2.46
Revenue and Profits:
Net Sales:
168 Million
(Quarterly Results - Jun 2026)
Net Profit:
-9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.35%
0%
20.35%
6 Months
18.3%
0%
18.3%
1 Year
24.94%
0%
24.94%
2 Years
101.45%
0%
101.45%
3 Years
46.32%
0%
46.32%
4 Years
44.42%
0%
44.42%
5 Years
-36.31%
0%
-36.31%
Chongqing Lummy Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-14.91%
EBIT Growth (5y)
7.05%
EBIT to Interest (avg)
-10.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
0.35
Tax Ratio
18.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.72
EV to EBIT
-26.65
EV to EBITDA
-35.92
EV to Capital Employed
3.46
EV to Sales
5.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.98%
ROE (Latest)
-7.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
168.20
182.20
-7.68%
Operating Profit (PBDIT) excl Other Income
2.90
3.10
-6.45%
Interest
1.10
4.00
-72.50%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-9.10
-13.60
33.09%
Operating Profit Margin (Excl OI)
-53.70%
-48.20%
-0.55%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -7.68% vs -6.37% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 33.09% vs 83.33% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
769.00
784.90
-2.03%
Operating Profit (PBDIT) excl Other Income
-47.70
-66.90
28.70%
Interest
13.90
11.20
24.11%
Exceptional Items
-60.20
4.70
-1,380.85%
Consolidate Net Profit
-126.50
-80.10
-57.93%
Operating Profit Margin (Excl OI)
-132.10%
-157.30%
2.52%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.03% vs -11.14% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -57.93% vs -701.00% in Dec 2024
About Chongqing Lummy Pharmaceutical Co., Ltd. 
Chongqing Lummy Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






